Showing results (831-840 of 1,839) with videos related to
Sort By:
Pageof 184
ESMO Open|June 22, 2023
Incidence, clinicopathological features, and clinical outcomes of low HER2 expressed, inoperable, advanced, or recurrent gastric/gastroesophageal junction adenocarcinomaI Nakayama, D Takahari, K Chin, et al.ESMO Open|June 22, 2023
Randomized phase II adjuvant trial to compare two treatment durations of icotinib (2 years versus 1 year) for stage II-IIIA EGFR-positive lung adenocarcinoma patients (ICOMPARE study)C Lv, R Wang, S Li, et al.ESMO Open|June 30, 2023
Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing resultsE B Garon, M Reck, K Nishio, et al.ESMO Open|May 27, 2023
Efficacy of immunotherapy in mismatch repair-deficient advanced colorectal cancer in routine clinical practice. An AGEO studyE Alouani, M Mercier, C Flecchia, et al.ESMO Open|March 11, 2026
Somatic and germline genomic variation in thymic carcinomasF Tettamanzi, C De Carlo, C Cappadona, et al.ESMO Open|March 12, 2026
A prospective study for brain metastasis imaging screening in patients with advanced HER2-positive or triple-negative breast cancerG M Kim, M H Kim, H S Park, et al.ESMO Open|March 5, 2026
Quality-of-life outcomes with pimitespib in patients with advanced gastrointestinal stromal tumor: results from the randomized, double-blind, placebo-controlled, phase III, CHAPTER-GIST-301 studyY Komatsu, N Taira, Y Kurokawa, et al.ESMO Open|April 1, 2026
Gene testing and prognosis in post-operative recurrent non-small-cell lung cancer: subgroup analyses of WJOG15421LT Matsubara, T Sakamoto, T Takahama, et al.ESMO Open|March 21, 2026
Overall survival from the open-label phase II trial of palbociclib in patients with advanced well-differentiated/dedifferentiated liposarcomaO O Babatunde, K Seier, G Schwartz, et al.Pageof 184